| Abstrakt: |
Illumina, Inc. (NASDAQ: ILMN) today announced that it has committed to invest $100M in a new venture capital firm that is strategically aligned with Illumina’s vision to improve human health by unlocking the power of the genome. Illumina Ventures was established by Nicholas Naclerio, Ph.D., Illumina’s former Senior Vice President, Corporate and Venture Development. The independently managed firm will pursue investments in early stage companies that are pioneering new applications of nucleic acid sequencing, developing products that will expand the genomics ecosystem, and utilizing genomics to improve human health. [ABSTRACT FROM PUBLISHER] |
